Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
News and updates for Travere Therapeutics, Inc. (TVTX) center on its work as a biopharmaceutical company focused on rare kidney, liver and metabolic diseases. Company announcements frequently highlight progress with FILSPARI (sparsentan), an oral, non-immunosuppressive therapy approved to slow kidney function decline in adults with primary IgA nephropathy (IgAN), and under supplemental FDA review as a potential treatment for focal segmental glomerulosclerosis (FSGS).
Investors following TVTX news can track regulatory milestones such as FDA review timelines, PDUFA target action dates and review extensions for the FILSPARI sNDA in FSGS. Travere also reports new clinical data from the Phase 3 DUPLEX and Phase 2 DUET studies in FSGS, as well as from PROTECT, SPARTAN and real-world analyses in IgAN. These updates often focus on proteinuria reduction, kidney function outcomes and correlations between biomarker changes and long-term kidney failure risk.
Travere’s news flow includes financial results and preliminary revenue updates, typically furnished via press releases and Form 8‑K filings, along with commentary on commercial performance of FILSPARI in IgAN. The company also issues releases on pipeline developments, including the planned restart of the pivotal Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria (HCU) and long-term metabolite reduction data from the COMPOSE study.
Additional news items cover partnership activities with CSL Vifor and Renalys Pharma, anticipated regional filings and launches, and Travere’s participation in major medical and investor conferences such as the American Society of Nephrology Kidney Week and large healthcare investment meetings. This page aggregates these developments so readers can follow how clinical, regulatory, commercial and partnership events may shape the company’s rare disease portfolio over time.
Travere Therapeutics (NASDAQ: TVTX) announced on February 10, 2023, that its Compensation Committee granted inducement equity grants to six new employees, totaling 17,700 restricted stock units (RSUs). These RSUs, part of Travere's 2018 Equity Incentive Plan, were awarded outside the plan as an inducement for the new hires, as per Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, contingent on the employees’ continued service with the company.
Travere Therapeutics, Inc. (NASDAQ: TVTX) announced its participation in two significant upcoming conferences. The SVB Securities Global Biopharma Conference is scheduled for February 15, 2023, at 3:00 p.m. ET, followed by the Barclays Global Healthcare Conference on March 15, 2023, at 11:15 a.m. ET. Live webcasts of each presentation will be available on Travere's Investor page, with replays accessible for up to 30 days post-event. Travere is dedicated to developing therapies for patients facing rare diseases, focusing on their urgent treatment needs and striving to offer hope through innovative solutions.
Travere Therapeutics (NASDAQ: TVTX) announced on January 10, 2023, that its Compensation Committee granted inducement equity grants to three new employees.
The grants include stock options for 25,000 shares and restricted stock units (RSUs) for 23,000 shares. The stock options have an exercise price of $20.38 and a 10-year term, vesting over four years, while RSUs also vest over four years. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are designed to attract new talent.
Travere Therapeutics (NASDAQ: TVTX) is set for a pivotal year in 2023, anticipating FDA approval for sparsentan for IgA nephropathy (IgAN) by February 17, followed by EMA approval later in the year. The company expects net product sales of $201 million for 2022, with approximately $450 million in cash reserves. Key clinical developments include the Phase 3 DUPLEX Study for focal segmental glomerulosclerosis (FSGS) and the initiation of a Phase 3 program for pegtibatinase, aimed at treating classical homocystinuria (HCU). Full financial results will be disclosed in late February.
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) announced that Eric Dube, Ph.D., CEO, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 11:15 a.m. PT. A live webcast will be available on the company's website, with an archived replay accessible for 30 days.
Travere Therapeutics focuses on developing therapies for rare diseases, collaborating with the community to understand patient needs and deliver impactful treatments.
Travere Therapeutics (NASDAQ: TVTX) announced the grant of inducement equity awards covering 124,100 shares to 11 new employees. This includes inducement stock options for 65,000 shares and 59,100 restricted stock units (RSUs). The stock options have an exercise price of $18.90 per share and vest over four years. The RSUs also vest over four years with similar terms. These grants were made outside the 2018 Equity Incentive Plan as a condition of employment, compliant with Nasdaq Listing Rule 5635(c)(4).
Travere Therapeutics (NASDAQ: TVTX) announced the grant of inducement equity covering 173,000 shares to 12 new employees on November 10, 2022. This includes inducement stock options for 90,000 shares and restricted stock units (RSUs) for 83,000 shares, granted outside the 2018 Equity Incentive Plan to comply with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $22.11 per share, vesting over four years, while the RSUs will also vest over the same period, contingent on continued service with the company.
Travere Therapeutics has launched the RKD & Me campaign in partnership with the IgA Nephropathy Foundation and NephCure Kidney International. The campaign aims to raise awareness of rare kidney disease (RKD) by sharing personal stories from those affected. Approximately 60-80 individuals per 100,000 in the U.S. are living with RKD, often facing challenges in diagnosis and support due to low public awareness. The initiative includes a platform for the RKD community to share their experiences and insights, helping to foster understanding and connection.
Travere Therapeutics (NASDAQ: TVTX) will participate in several key healthcare conferences in November and December 2022. Key events include:
- Jefferies 2022 London Healthcare Conference on November 16 at 4:25 p.m. GMT.
- 5th Annual Evercore ISI HealthCONx Conference on November 29 at 1:25 p.m. ET.
- Piper Sandler Healthcare Conference on December 1 at 10:30 a.m. ET.
- BofA Securities 2022 Biotech SMID Cap Conference on December 7 at 12:15 p.m. ET.
Live webcasts will be accessible on the company’s website.
Travere Therapeutics (TVTX) announced major developments in its drug pipeline and financial results for Q3 2022. The EMA has accepted the CMA application for sparsentan for IgAN, with a decision expected in H2 2023. The FDA has extended the PDUFA date to February 17, 2023. Q3 net product sales reached $50.8 million, down from $54.2 million YoY, contributing to total revenue of $53.5 million. R&D expenses increased to $59.3 million. The company reported a net loss of $69.7 million. Cash reserves stood at $506.3 million, supporting ongoing programs in rare kidney diseases.